Hormonal
GLP-1 RA treatment results in significantly lower weight loss in individuals of African and admixed American ancestry compared to European ancestry, after adjusting for baseline factors.
If you are of African or admixed American ancestry, you may experience slightly less weight loss from GLP-1 RA drugs compared to European ancestry individuals, even when adjusting for baseline weight and other factors. This may be due to biological or socioeconomic factors. Close monitoring and potential dose adjustments may be necessary.
Compared with individuals of European ancestry, all other ancestry groups had a lower change in body weight. However, this effect was statistically significant only among GLP1-RA users of African (β = 0.76% weight change from baseline weight, P = 0.02) and admixed American (β = 0.87% weight change from baseline weight, P = 3 × 10−3) ancestries.
Why this rating
Large multi-ancestry study with statistically significant findings for specific groups.
Source
Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery
J German et al. · Nature Medicine · 2025
DOI 10.1038/s41591-025-03645-3
More from this paper
- Polygenic scores for BMI and Type 2 Diabetes do not significantly predict weight loss outcomes in patients treated with GLP-1 receptor agonists.Good
- A higher polygenic score for BMI is associated with lower weight loss following bariatric surgery, although the effect size is modest and attenuates in sensitivity analyses.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →